

Use of HypoThermosol® in Clinical Trials of New Regenerative Medicine Products & Therapies

Clinical Indication	Administration Route	Reagent Status	Pre-Clinical	Phase I	Phase II	Phase III	Approved
Stress Urinary Incontinence	N/A	Ancillary	✓	✓	✓	✓	
Post MI CHF	IM – ventricular	Excipient	✓	✓	✓	✓	
Multiple Sclerosis	Subcutaneous	Excipient	✓		✓		
Ulcerative Colitis	Intravenous	Excipient	✓		✓		
Wound healing	Subcutaneous	Excipient	✓	✓	✓		
Dilated Cardiomyopathy	Intraventricular	Excipient	✓	✓	✓		
Critical Limb Ischemia	Intramuscular	Excipient	✓	✓	✓	✓	
Stroke	Intracranial	Excipient	✓	✓			
Urinary Sphincter Repair	N/A	Ancillary	✓	✓	✓	✓	
Fecal Incontinence	N/A	Ancillary	✓	✓			
Ischemic Heart Disease	N/A	Ancillary	✓	✓			
Safety Study	Intralymphatic	Excipient	✓	✓			
PAD	Intramuscular	Excipient	✓	✓			
Organ Rejection	Intravenous	Excipient	✓	✓			
Heart Failure	N/A	Ancillary	✓	✓	✓		

Information deemed accurate as of September 3, 2013, as sourced from www.clinicaltrials.gov and direct customer communication. BioLife Solutions has no obligation to update this information. Please contact support@biolifesolutions.com if you have a question or comment about this information.